GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Galcanezumab-gnlm (Emgality), subcutaneous injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Emgality - labeled renal guidance

Product / population
Galcanezumab-gnlm (Emgality), subcutaneous injection
Renal method
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 17, posted Jun 18, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Emgality - product and source limitations

A regimen for severe impairment cannot be derived from these data.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Emgality - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Galcanezumab-gnlm (Emgality), subcutaneous injection

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 17, posted Jun 18, 2026
Retrieved: 2026-11-07

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Prescribing information, renal precautions and clinical pharmacology

The galcanezumab renal analysis did not include patients with CrCl below 30 mL/min. A regimen for severe impairment cannot be derived from these data.

RDM74-emgality-official-1 · Source locator: Renal guidance: Prescribing information, renal precautions and clinical pharmacology

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33a147be-233a-40e8-a55e-e40936e28db0
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 17, posted Jun 18, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
31f39ca8e564d3170c7d187b02c96f4567f5693f06ab56f8a774a6d372254d9c

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-emgality&s1=RDM74-emgality-official&h1=f13d1a287964f275c9b3aeb778554155e116abee650ccffd321c534898af35aa

Top